-- Mark A Goldsmith, Director, President and Chief Executive Officer, on April 15, 2026, sold 120,000 shares in Revolution Medicines (RVMD) for $18,010,488. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 999,606 common shares of the company, with 276,698 shares held directly and 722,908 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1628171/000161071726000146/xslF345X05/form4.xml